REGENXBIO Inc. (NASDAQ:RGNX) Q4 2022 Earnings Conference Call February 28, 2023 4:30 PM ET

Company Participants

Patrick Christmas - Chief Legal Officer

Ken Mills - Chief Executive Officer

Steve Pakola - Chief Medical Officer

Vit Vasista - Chief Financial Officer

Conference Call Participants

Dane Leone - Raymond James

Lisa Walter - RBC Capital Markets

Andreas Argyrides - Wedbush Securities

Caroline Palomeque - Berenberg

Operator

Hello, and thank you for standing by. Welcome to the Q4 and Full Year 2022 REGENXBIO Earnings Call. At this time, all participants are in a listen-only mode. After the prepared remarks, there will be a question-and-answer session. Instructions will be given at that time. As a reminder, this call is being recorded.

It is now my pleasure to introduce, Chief Legal Officer, Patrick Christmas. You may begin.

Patrick Christmas

Good afternoon, and thank you for joining us today. Earlier this afternoon, REGENXBIO released financial and operating results for the fourth quarter and full year ended December 31, 2022. The press release is available on our website at www.regenxbio.com.

Today's conference call will include forward-looking statements regarding our financial outlook in addition to regulatory and product development plans. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ from those forecasted and can be identified by words such as expect, plan, will, may, anticipate, believe, should, intend, and other words of similar meaning.

Any such forward-looking statements are not guarantees of future performance and involve certain risks and uncertainties. These risks are described in the risk factors and the management's discussion and analysis sections of REGENXBIO's annual report on Form 10-K for the full year ended December 31, 2022, and comparable Risk Factors sections of REGENXBIO's quarterly reports on Form 10-Q, which are on file with the Securities and Exchange Commission and available on the SEC's website.

Any information we provide on this conference call is provided only as of the date of this call, February 28, 2023, and we undertake no obligation to update any forward-looking statements we may make on this call on account new information, future events or otherwise.

Please be advised that today's call is being recorded and webcast. In addition, any unaudited or pro forma financial information that may be provided is preliminary and does not report to project financial positions or operating results of the company. Actual results may differ materially.

I would now like to turn the call over to Ken Mills, CEO of REGENXBIO. Ken?